Skip to main content
Clinical Trials/NCT03735017
NCT03735017
Completed
Not Applicable

Immersive Virtual Walking Treatment for Neuropathic Pain in Spinal Cord Injury

University of Alabama at Birmingham1 site in 1 country27 target enrollmentJune 16, 2018

Overview

Phase
Not Applicable
Intervention
Not specified
Conditions
Spinal Cord Injuries
Sponsor
University of Alabama at Birmingham
Enrollment
27
Locations
1
Primary Endpoint
Pain Intensity as assessed by Numeric Rating Scale
Status
Completed
Last Updated
4 years ago

Overview

Brief Summary

This study will examine the effectiveness of one of two virtual reality treatments on neuropathic pain in individuals with spinal cord injury.

Detailed Description

The investigators are investigating the effectiveness of one of two possible investigational virtual reality treatments on neuropathic pain in individuals with spinal cord injury. Participants will be randomized to one of these two treatments.

Registry
clinicaltrials.gov
Start Date
June 16, 2018
End Date
July 30, 2019
Last Updated
4 years ago
Study Type
Interventional
Study Design
Parallel
Sex
All

Investigators

Responsible Party
Principal Investigator
Principal Investigator

Zina Trost

Assistant Professor

University of Alabama at Birmingham

Eligibility Criteria

Inclusion Criteria

  • Individuals with complete paraplegic spinal cord injury who report chronic neuropathic pain
  • Individuals with persistent spinal cord injury neuropathic pain
  • More than one - year post injury
  • Stable medication regimen for the past month

Exclusion Criteria

  • Conditions that impair movement of the arms
  • Significant cognitive impairment as suggested by apparent incomprehension of screening questions as judged by the evaluator
  • For those for whom voluntary arm movement would cause sufficient discomfort (\>4/10) that could prevent trial completion will be excluded from participation

Outcomes

Primary Outcomes

Pain Intensity as assessed by Numeric Rating Scale

Time Frame: Baseline - Final assessment (average 1 week post treatment)

The Numeric Rating Scale (NRS) measures pain intensity measured via 0-10 numeric rating scale. Range of scores: 0-10

Neuropathic Pain Qualities as assessed by Neuropathic Pain Scale

Time Frame: Baseline - Final assessment (average 1 week post treatment)

The Neuropathic Pain Scale (NPS) was designed to assess the distinct pain qualities associated with neuropathic pain.The NPS consists of 10 items. Seven of the 10 items contain the words intense, sharp, hot, dull, cold, and itchy to characterize the patient's pain and the word sensitive to describe the patient's pain reaction to light touch or clothing.One item describes the time quality of the pain (all the time or some of the time). The ninth item describes the overall unpleasantness of the pain, whereas the last item indicates the intensity of the deep and surface pain. In the NPS each item is rated separately. All the items are rated 0-10 scale, with higher score indicative of more neuropathic pain for each type of respective pain. Range of scores: 0-10 for each item.

Neuropathic Pain Diagnosis as assessed by Doleur Neuropatique 4

Time Frame: Baseline - Final assessment (average 1 week post treatment)

Doleur Neuropatique 4 is a 10 item survey that evaluates neuropathic pain following central and neurological lesions. It has components of how the pain feels to the patient (e.g. burning, cold, electrical shocks, tingling, hypoaesthesia). Responses to each item is yes or no, with each yes response equaling one point. Range of scores: 0-10. 4/10 and greater indicate neuropathic pain.

Pain Interference specific to spinal cord injury as assessed by International Spinal Cord Injury Pain Basic Data Set version 2.0

Time Frame: Baseline - Final assessment (average 1 week post treatment)

Pain interference measured International Spinal Cord Injury Pain Basic Data Set version 2.0 interference items. There are 3 pain interference items using a 0-10 numeric rating scale for each item. Items can be assessed by summing the score or by individual assessment of items. Summed range of scores: 0-30. Individual item range of scores: 0-10

Pain Interference as assessed by Brief Pain Inventory

Time Frame: Baseline - Final assessment (average 1 week post treatment)

Pain interference measured by Brief Pain Inventory interference items. 7 items each use a 0-10 scale. Item scores may be assessed individually, or by taking the average score of all items. Range of Scores: 0-10. Increased scores indicate higher levels of interference due to pain.

Secondary Outcomes

  • Patient Treatment Evaluation as assessed by the Ease of Usefulness, Satisfaction, and Ease of Use Questionnaire(Final assessment (average 1 week post treatment))
  • Patient Treatment Evaluation as assessed by the Patient Global Impression of Change Scale(Final assessment (average 1 week post treatment))
  • Patient Treatment Evaluation as assessed by the Modified Treatment Evaluation Inventory(Final assessment (average 1 week post treatment))
  • Patient Treatment Evaluation as assessed by Semi-structured Qualitative Interviewing(Final assessment (average 1 week post treatment))
  • Quality of Life and Participation are assessed by the SF-36 Walk-Wheel(Baseline - Final assessment (average 1 week post treatment))
  • Quality of Life is assessed by Satisfaction with Life Scale(Baseline - Final assessment (average 1 week post treatment))
  • Depression and mood are assessed by the Patient Health Questionnaire -9(Baseline - Final assessment (average 1 week post treatment))
  • Perceived Disability is assessed by the Pain Disability Index(Baseline - Final assessment (average 1 week post treatment))
  • Absorption is assessed by the Tellegen Absorption Scale(Baseline)
  • Immersive Tendencies are assessed by the Immersive Tendencies Questionnaire(Baseline)
  • fMRI Imaging(Baseline - Final assessment (average 1 week post treatment))

Study Sites (1)

Loading locations...

Similar Trials